The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to the government's growth agenda". The paper says executives have warned that policies pursued by the government will make the UK a less attractive place to invest.

Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in northwest England.

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government.

AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Merseyside, blaming a reduction in government support. The pharmaceutical giant announced its decision just two days after Chancellor Rachel Reeves set out Labour's plan to go "further and faster" to boost economic growth.

In a shock move, AstraZeneca has ditched a plan to invest £450 million ($558 million) in a new vaccine manufacturing plant in the UK, after the government reduced the offer on the table to support the project.

AstraZeneca announced it will not proceed with plans for a 450 million pound vaccine manufacturing plant in Speke, Liverpool. The decision was influenced by discussions with the current government and changes in the financial offer.

AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.

AstraZeneca has axed plans to build a £450million vaccine manufacturing plant because of a lack of Government support in the latest blow to Rachel Reeves. The Labour government last summer tried to reduce the amount of state support provided to the Liverpool project from about £90million to £40million,